GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
39.80
+0.03 (+0.08%)
At close: 4:01PM EDT

40.30 +0.51 (1.28%)
Pre-Market: 4:09AM EDT

Stock chart is not supported by your current browser
Previous Close39.77
Open40.11
Bid40.30 x 1300
Ask40.35 x 1000
Day's Range39.76 - 40.14
52 Week Range34.52 - 42.36
Volume1,710,707
Avg. Volume2,428,989
Market Cap102.309B
Beta0.66
PE Ratio (TTM)71.84
EPS (TTM)0.55
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.17 (5.29%)
Ex-Dividend Date2018-05-10
1y Target Est42.19
Trade prices are not sourced from all markets
  • The traders weigh in on Square, GlaxoSmithKline and Dropb...
    CNBC Videos5 days ago

    The traders weigh in on Square, GlaxoSmithKline and Dropb...

    The "Halftime Report" traders take viewer questions on ORBCOMM, Square, GlaxoSmithKline, Royal Dutch Shell and Dropbox.

  • Cigna, Alibaba and GlaxoSmithKline are the Yahoo Finance charts of the day.
    Yahoo Finance Video8 days ago

    Cigna, Alibaba and GlaxoSmithKline are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Cigna (CI): Shares are up in early trade, at around .23%.  Activist Carl Icahn went public with his opposition to Cigna's proposed $54 billion purchase of Express Scripts, saying that the health insurer is overpaying and that Amazon.com represents an "existential threat" to pharmacy benefit managers. Alibaba (BABA): Shares are up here, around 1.08%.  Reuters reports that Alibaba will reportedly merge its food delivery units and raise funds for the combined business. GlaxoSmithKline (GSK): Shares up here, around 1.83%.  The drugmaker has named Iain MacKay from global bank HSBC as its new chief financial office as of January 14, 2019. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Reuters22 minutes ago

    FTSE steadies as GSK leads health stocks, miners weigh

    The UK's top share index steadied on Wednesday as a fall across mining stocks capped results-driven gains, with GlaxoSmithKline a standout riser after the result of a clinical trial boosted hopes for its HIV business. The blue chip FTSE 100 (.FTSE) index was flat in percentage terms at 7,609.19 points by 0854 GMT, while mid caps (.FTMC) gained 0.2 percent. Global markets more broadly have been hit by financial crisis in Turkey, though both the FTSE and European markets have stabilised.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters1 hour ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • The Wall Street Journal1 hour ago

    [$$] European Corporate Roundup for Wednesday

    European Corporate Roundup for Wednesday Admiral Group 1H Interim Profit Rose on Motor-Unit Growth Admiral Group PLC said Wednesday that its first-half profit rose on growth in its core U.K. motor-insurance business, despite poor weather hurting its household unit.

  • Reuters2 hours ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline (GSK.L) and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences (GILD.O), the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Financial Times2 hours ago

    [$$] GSK sees positive signs from trials of reduced HIV treatment

    GlaxoSmithKline’s HIV division has welcomed the results of a trial that could see the drug regime of patients cut from a daily dose of three drugs to a monthly injection of two. ViiV Healthcare hopes that developing the two-drug products will boost GSK’s share of the $20bn-a-year market for HIV treatment, addressing toxicity concerns among people living with HIV by reducing the number of medicines they need to take. In the case of the injectable version, ViiV wants to be able to free HIV patients from having to take daily treatment.

  • Reuters3 hours ago

    Long-acting injection boosts hopes for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's ...

  • A Look at Novo Nordisk’s Human Insulin and Obesity Business
    Market Realist19 hours ago

    A Look at Novo Nordisk’s Human Insulin and Obesity Business

    In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.

  • Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
    Market Realist19 hours ago

    Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018

    GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.

  • What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
    Market Realist21 hours ago

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.

  • GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
    Market Realist22 hours ago

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.

  • Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
    Motley Foolyesterday

    Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

    Which stock wins in a matchup between these two big pharma companies?

  • The Wall Street Journal2 days ago

    [$$] Orchard Therapeutics Raises $150 Million After GlaxoSmithKline Deal

    Orchard Therapeutics has raised $150 million after bulking up its portfolio of gene therapies through an agreement with GlaxoSmithKline.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist2 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...

  • Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
    Market Realist2 days ago

    Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?

    Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.

  • Analyzing GlaxoSmithKline’s Revenue Trends
    Market Realist2 days ago

    Analyzing GlaxoSmithKline’s Revenue Trends

    In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.

  • How GlaxoSmithKline’s Valuation Compares with Peers’
    Market Realist2 days ago

    How GlaxoSmithKline’s Valuation Compares with Peers’

    Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017. 

  • Reuters2 days ago

    Orchard raises $150 million to expand after GSK gene therapy deal

    Anglo-American biotech company Orchard Therapeutics has raised a further $150 million (117.7 million pounds) to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million (109.8 million pounds). The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or "bubble baby" disease. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion (6.8 billion pounds) acquisition of AveXis in April - but products sold to Orchard are viewed as too niche for GSK as it refocuses its drug research under CEO Emma Walmsley.

  • Reuters2 days ago

    Orchard raises $150 mln to expand after GSK gene therapy deal

    Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million. The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or "bubble baby" disease. Gene therapy is a hot area for drug research - highlighted by Novartis's $8.7 billion acquisition of AveXis in April - but products sold to Orchard are viewed as too niche for GSK as it refocuses its drug research under CEO Emma Walmsley.

  • In $270M Peninsula vaccine company buyout, small players look to be big shots
    American City Business Journals5 days ago

    In $270M Peninsula vaccine company buyout, small players look to be big shots

    A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.

  • Examining Pfizer’s Performance by Segment in Q2 2018
    Market Realist8 days ago

    Examining Pfizer’s Performance by Segment in Q2 2018

    As we discussed earlier, Pfizer’s (PFE) business is separated into two segments: Innovative Health and Essential Health. The Innovative Health segment contributes over 61.4% of Pfizer’s total revenue. This rise included a 5% rise in operating revenue and a 3% favorable impact of foreign exchange.

  • Cigna up slightly, Alibaba pushing higher, GlaxoSmithKline on the move
    Yahoo Finance8 days ago

    Cigna up slightly, Alibaba pushing higher, GlaxoSmithKline on the move

    Cigna, Alibaba and GlaxoSmithKline are the Yahoo Finance charts of the day.

  • TheStreet.com8 days ago

    GlaxoSmithKline Gets a Boost

    In this daily bar chart of GSK, below, we can see how prices have rallied from the November/December lows. The daily On-Balance-Volume (OBV) line turned higher in November with the price action but it has leveled off in recent months. The Moving Average Convergence Divergence (MACD) oscillator is holding just above the zero line and renewed price strength should turn this indicator bullish again.

  • Financial Times8 days ago

    [$$] GSK unveils CFO succession plans as it pursues cost-cutting push

    Iain Mackay has been appointed as chief financial officer at GlaxoSmithKline in succession to Simon Dingemans as the drugmaker seeks to cut costs as part of a restructuring. Mr Mackay, who has been group finance director at HSBC for the past eight years, will join in January, as the company accelerates its drive to improve the performance of its pharma division, identified by chief executive Emma Walmsley as her top priority. Last month, Ms Walmsley announced a “major restructuring programme” that aims to reduce costs by £400m a year by 2021.